Follow The Filings

TNGX Tango Therapeutics

Tango Therapeutics earnings company data as of 12:25 PM ET 11/17

  • 0 of 1 EPS beats

History

1 period, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 9 Nov EPS -0.35 -0.39 Miss
Rev — — —

Insider trades

Open-market buys and sales by TNGX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TNGX insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $7.4M sold by 3 insiders under 10b5-1 plans
  1. John B. Ketchum Director
    Planned sale
    $80K 3,333 shares at $24.08 13% of stake
    Traded Nov 17 Filed Nov 19
  2. Adam Crystal President, R&D
    Planned sale
    $125K 5,000 shares at $25.00 4.1% of stake
    Traded Nov 11 Filed Nov 13
  3. Adam Crystal President, R&D
    Planned sale
    $112K 5,000 shares at $22.42 4.1% of stake
    Traded Nov 2 Filed Nov 4
  4. Jessica Newcomb Principal Accounting Officer
    Planned sale
    $158K 7,031 shares at $22.42 12% of stake
    Traded Nov 2 Filed Nov 4
  5. Adam Crystal President, R&D
    Planned sale
    $661K 27,000 shares at $24.47 19% of stake
    Traded Oct 1 Filed Oct 5
  6. Jessica Newcomb Principal Accounting Officer
    Planned sale
    $199K 8,200 shares at $24.22 12% of stake
    Traded Sep 22 Filed Sep 24
  7. Adam Crystal President, R&D
    Planned sale
    $604K 27,000 shares at $22.37 19% of stake
    Traded Sep 1 Filed Sep 3
  8. Adam Crystal President, R&D
    Planned sale
    $736K 27,000 shares at $27.24 19% of stake
    Traded Aug 3 Filed Aug 5
  9. Adam Crystal President, R&D
    Planned sale
    $799K 27,000 shares at $29.59 19% of stake
    Traded Jul 1 Filed Jul 2
  10. Adam Crystal President, R&D
    Planned sale
    $618K 27,000 shares at $22.87 19% of stake
    Traded Jun 1 Filed Jun 3
  11. Adam Crystal President, R&D
    Planned sale
    $573K 27,000 shares at $21.23 19% of stake
    Traded May 1 Filed May 5
  12. Adam Crystal President, R&D
    Planned sale
    $962K 38,460 shares at $25.00 26% of stake
    Traded Apr 15 Filed Apr 16
  13. Adam Crystal President, R&D
    Planned sale
    $572K 27,000 shares at $21.20 19% of stake
    Traded Apr 1 Filed Apr 2
  14. Adam Crystal President, R&D
    Planned sale
    $241K 12,000 shares at $20.11 9.6% of stake
    Traded Mar 25 Filed Mar 27
  15. Adam Crystal President, R&D
    Planned sale
    $304K 20,251 shares at $15.00 15% of stake
    Traded Mar 5 Filed Mar 9

Also filed in the last 12 months, not counted as buying or selling: 12 stock grants, 11 option exercises, and 6 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
SCHEDULE 13G/A —
8-K 7.01,8.01,9.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
424B5
8-K 8.01,9.01
8-K/A 5.02,7.01,9.01
8-K 5.02
8-K 5.02,9.01
424B5
8-K 1.01,9.01
8-K 7.01,8.01,9.01
424B5
8-K 5.07
SCHEDULE 13G/A —

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf